Company Deep Dive
Read the full research report: business segments breakdown, earnings transcripts review, management credibility analysis, competitive landscape, and scenarios.
PCRX
STRONG BUYFLAGPacira BioSciences, Inc. · Healthcare · United States · $1.0B · Avg Vol: $13M/d
Pacira BioSciences depends heavily on a single long-acting local anaesthetic whose key patent protection was invalidated in litigation, opening the door to generic entry, and it carries convertible debt against that concentrated revenue base. That patent outcome is a specific, nameable adverse development. The strong momentum does not offset it, so this is a flag.
COMPANY DESCRIPTION
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing, commercializing, and manufacturing non-opioid pain management products, with its flagship EXPAREL providing long-acting local analgesia for postsurgical pain. The company benefits from its proprietary drug delivery technology, DepoFoam, and the strong market position of EXPAREL as a leading non-opioid solution, creating a significant competitive moat in the growing demand for opioid alternatives.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 666.8M | 675.0M | 701.0M | 726.4M | 2.9% | 734.9M | 767.8M | 831.3M | 7.0% |
| EPS | 0.35 | 0.91 | -2.15 | 0.16 | -23.0% | 0.13 | 0.17 | 0.22 | 17.3% |
| Shares | 45.9M | 46.5M | 46.2M | 41.1M | -10.5% | 39.3M | — | — | — |
| Debt | 763.4M | 586.0M | 638.9M | 418.2M | -18.2% | 411.2M | — | — | — |
| Equity | 775.0M | 870.1M | 778.3M | 693.1M | -3.7% | — | — | — | — |
| Op CF | 145.3M | 154.6M | 189.4M | 152.0M | 1.5% | 142.2M | — | — | — |
| Inv CF | -225.2M | 77.5M | -83.3M | 99.5M | — | — | — | — | — |
| Fin CF | -401.5M | -183.0M | 17.4M | -369.6M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PCRX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| PCRX | Pacira BioSciences, Inc.(you) | $1.0B | 93 | STRONG BUY |
| COLL | Collegium Pharmaceutical, Inc. | $1.1B | 95 | STRONG BUY |
| GTII.CN | Green Thumb Industries Inc. | $1.6B | 93 | STRONG BUY |
| TRLV | Trulieve Cannabis Corp. | $1.6B | 89 | STRONG BUY |
| IRWD | Ironwood Pharmaceuticals, Inc. | $611M | 97 | STRONG BUY |
| ANIP | ANI Pharmaceuticals, Inc. | $1.8B | 97 | STRONG BUY |
| BCRX | BioCryst Pharmaceuticals, Inc. | $2.4B | 88 | STRONG BUY |
| AMPH | Amphastar Pharmaceuticals, Inc. | $825M | 75 | BUY |
| PAHC | Phibro Animal Health Corporation | $1.4B | 73 | BUY |
| PBH | Prestige Consumer Healthcare Inc. | $2.4B | 81 | STRONG BUY |
Peer medians: ROE -25.6% · P/E 27.6x · Gross margin 50.5%